Introduction {#S1}
============

Central nervous system (CNS) disease and disorders are posing great challenge for mankind and is the fastest growing area appealing for the attention of researchers. Today, neurological disorders are among the highest reasons for causing death and disability in the world. The contribution of CNS disorders to the global burden of disease is increasing and globally, in 2016, neurological disorders were the leading cause of disability-adjusted life-years (DALYs) \[276 million (95% UI 247--308)\] and second leading cause of deaths \[9⋅0 million (8⋅8--9⋅4)\] ([@B44]). To date, the diagnosis and treatment of the neurological disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), head trauma, brain tumor, and epilepsy are still a challenging task ([@B10]). A wide spectrum of potential drugs has been investigated to treat several neurological disorders but their therapeutic success is still limited due to range of challenges. One of the most common challenge is the difficulty in delivering agents such as drugs, nucleic acids, proteins, imaging agents and other macromolecules to the CNS across the peripheral barriers, namely blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB), particularly the BBB ([@B155]; [@B220]). [Figure 1](#F1){ref-type="fig"} showing different smuggling pathways of drug through which it may enter into the brain.

The current neurotherapeutics are associated with two major limitations i.e., before entering into brain cells they are pose to limited entry via BBB as insufficient entry in brain as well as of limited access to immune cells to brain ([@B123]; [@B132]). Most of the drugs used in neural diseases are lipophilic in nature having molecular weight greater 400--500 Da and not able to cross the BBB in pharmacologically significant quantity ([@B47]) hence do not pass in initial screening whereas small lipophilic molecules (alcohol and steroid hormones) penetrate via transcellular mechanism. However, the presence of different transporters on endothelial cells which are highly selective in nature also limits the drugs entry. Also the presence of Tight junctions (TJ) in endothelial membranes creates high transendothelial electrical resistance (TEER) (\>1000 W cm^2^) in cerebral microcapillaries ([@B57]). The endothelial cells of BBB restrict the passage or entry of endogenic/foreign materials. ATP-binding cassette (ABC) transporters present over the endothelial cells and restrict the therapeutic drug entry also along with neurotoxic agents/metabolites/hormones/mediators. These transporters are membrane proteins require ATP to transport materials through cell membranes. Multiple drug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1), which is well known as permeability glycoprotein (P-gp), multiple resistance protein 4 (MRP4) or ATP-binding cassette sub-family C member 4 (ABCC4), and breast cancer resistance protein (BCRP) or ATP-binding cassette sub-family G member2 (ABCG2) are members of this family ([@B7]). The BBB also maintains the ionic homeostasis at synapses, where it regulates the entry of potassium ions (k^+^), calcium (Ca^2+^), sodium (Na^+^) and maintains minimum optic concentrations.

The BBB is made up of monolayer of polarized endothelial cells connected by complex tight junctions, and its functionality is controlled by cells such as astrocytes, neurons, and pericytes. The complexity of BBB, the existence of high levels of efflux transport proteins including P-glycoproteins (P-gp) and Multidrug Resistant Protein-1 (MRP-1), and the expression of metabolic enzymes limits the entry of drug inside the brain ([@B197]).

Recently, efforts such as alterations in the permeability efficiency of the BBB, carrier and receptor-mediated drug delivery, have been adopted to overcome the obstacles faced during successful treatment, even though the impact of most of these strategies has been found not much effective. Lipidization of a molecule with a lipid layer, disruption of BBB by means of ultrasound technique or radiation therapy and use of nanomaterials are some methods to help drug delivery across BBB ([@B161]). Among these methods, nanotechnology-based drug delivery is a quite new as compare to conventional methods and promising approach in the field of neuro disorders, as nanocarriers have been proved efficacious in effectively traversing the BBB or BCSFB and thus effectively delivering drugs within the CNS to the target site ([@B188]; [@B70]; [@B220]; [@B105]). The [Table 1](#T1){ref-type="table"} describes the few of the FDA approved nanodrugs available clinically for different indications ([@B211]). The average size of human cells is 10--20 μm, where as the minimal diameter of blood capillaries are 6--9 μm, due to their nano size ranges nanomaterials get easily transported and internalizes by brain capillary endothelial cells via endocytosis and transcytosis mechanism of transport ([@B212]). Different nanocarriers of particle size between 1 and 100 nm have been emerged by the development of nanotechnology, among which polymeric nanoparticles (PNPs), solid lipid nanoparticles (SLNPs), liposomes, and micelles made their debut as nanocarriers for treatment of various neurological disorders. But, nowadays, newer and more advanced nanosystems, such as dendrimers, nanoemulsions ([@B20]), nanogels, nanosuspensions, and nanotubes, etc., which have shown great potential than previous delivery systems, developed by the nanotechnological approach ([@B164]; [@B220]; [@B144]; [@B3]). The selection of an appropriate nanocarrier system is a prerequisite for effective delivery of drug to CNS across BBB. The size, surface area, surface charge and morphology of nanocarriers have a remarkable impact on their passage across CNS barriers. The nanocarriers used in CNS drug delivery should have optimum size, surface area, surface charge and should be biodegradable, non-toxic, biocompatible, cost-effective and site-specific ([@B26]). Various nanodrug system such as polymers, micelles, liposomes, dendrimers, nanocrystals, SLNPs have been used to improve efficacy, safety physiological properties pharmacokinetics, and pharmacodynamics of drugs ([Figure 2](#F2){ref-type="fig"}) ([@B187]; [@B27]; [@B53]; [@B201]). The major targets in the development of nanomedicine are:

###### 

Clinically available FDA-approved nanoformulated drugs ([@B175]; [@B18]; [@B23]; [@B25]; [@B48]; [@B49]; [@B211]).

  Generic name                               Trade name (Manufacturer)                              Disease                                                                                  Advantages
  ------------------------------------------ ------------------------------------------------------ ---------------------------------------------------------------------------------------- -----------------------------------------------------------
  **Polymer NPs**                                                                                                                                                                            
  Copaxone (Teva)                            Glatimer acetate                                       Multiple sclerosis                                                                       Controlled clearance
  Eligard (Tolmar)                           Leuprolide acetate and polymer                         Prostate cancer                                                                          Extended circulation time, controlled payload delivery
  Adynovate (Shire)                          Antihemophilic factor (recombinant), pegylated         Hemophilia                                                                               Better protein stability, longer half-life
  Cimzia (UCB)                               Certolizumab pegol                                     Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis   Extended circulation time, greater stability *in vivo*
  Mircera (Vifor)                            Methoxy polyethylene glycol-epoetin beta               Anemia associated with CKD                                                               High aptamer stability
  Neulasta (Amgen)                           Pegfilgrastim                                          Chemotherapy-induced neutropenia                                                         High protein stability
  Krystexxa (Horizon)                        Pegloticase                                            Chronic gout                                                                             High protein stability
  Macugen (Bausch and Lomb)                  Pegaptinib                                             Neovascular AMD                                                                          High aptamer stability
  Adagen (Leadiant Biosciences)              Pegademase bovine                                      SCID                                                                                     Longer circulation time, decreased immunogenicity
  Oncaspar (Baxalta United States)           Pegaspargase                                           ALL                                                                                      High protein stability
  Pegasys (Genentech)                        Pegylated IFN alpha-2a                                 Hepatitis B, hepatitis C                                                                 High protein stability
  PegIntron (Merck)                          Pegylated IFN alpha-2b                                 Hepatitis C                                                                              Greater protein stability
  Somavert (Pfizer)                          Pegvisomant                                            Acromegaly                                                                               High protein stability
  Zilretta (Flexion Therapeutics)            Triamcinolone acetonide ER injectable suspension       Osteoarthritis knee pain                                                                 Extended release
  Plegridy (Biogen)                          Pegylated IFN beta-1a                                  Multiple sclerosis                                                                       High protein stability
  Rebinyn (Novo Nordisk)                     Coagulation factor IX (recombinant), glycopegylated    Hemophilia B                                                                             Prolonged half-life, higher drug levels between infusions
  Renvela (Genzyme); and Renagel (Genzyme)   Sevelamer carbonate; and Sevelamer HCl                 CKD                                                                                      Prolonged circulation time and therapeutic delivery
  **Liposome NPs**                                                                                                                                                                           
  DepoDur (Pacira Pharmaceuticals)           Liposomal morphine sulfate                             Postoperative analgesia                                                                  Prolonged release
  Marqibo (Spectrum Pharmaceuticals)         Liposomal vincristine                                  ALL                                                                                      High delivery to tumor site, decreased systemic toxicity
  Onivyde (Ipsen Biopharmaceuticals)         Liposomal irinotecan                                   Pancreatic cancer                                                                        High delivery to tumor site, decreased systemic toxicity
  Curosurf (Chiesi United States)            Poractant alfa                                         Respiratory distress syndrome                                                            High delivery with low volume, decreased toxicity
  Doxil (Janssen)                            Doxorubicin HCl liposome injection                     Karposi's sarcoma, ovarian cancer, multiple myeloma                                      High delivery to disease site, less systemic toxicity
  Abelcet (Sigma-Tau)                        Liposomal amphotericin B                               Lipid complex fungal infections                                                          Reduced toxicity
  AmBIsome (Gilead Sciences) B               Liposomal amphotericin                                 Fungal/protozoal infections                                                              Reduced nephrotoxicity
  Visudyne (Bausch and Lomb)                 Liposomal verteporfin                                  Wet AMD, ocular histoplasmosis, myopia                                                   Improved delivery to site of diseased vessels
  Vyxeos (Jazz Pharmaceuticals)              Liposomal daunorubicin and cytarabine                  AML, AML with myelody splasiarelated changes                                             Enhanced efficacy through synergistic delivery of
  **Micelle NPs**                                                                                                                                                                            
  Estrasorb (Novavax)                        Micellar estradiol                                     Vasomotor symptoms in menopause                                                          Controlled delivery
  **Inorganic NPs**                                                                                                                                                                          
  Ferrlecit (Sanofi-Aventis)                 Sodium ferric gluconate complex in sucrose injection   Iron deficiency in CKD                                                                   Increased dose
  Infed (Actavis Pharma)                     Iron dextran                                           Iron deficiency in CKD                                                                   Increased dose
  Venofer (American Regent)                  Iron sucrose                                           Iron deficiency in CKD                                                                   Increased dose
  Dexferrum (American Regent)                Iron dextran                                           Iron deficiency in CKD                                                                   Increased dose
  Feraheme (AMAG Pharmaceuticals)            Ferumoxytol                                            Iron deficiency in CKD                                                                   Prolonged, steady release with less frequent dosing
  **Protein NPs**                                                                                                                                                                            
  Ontak (Eisai)                              Denileukin diftitox                                    Cutaneous T-cell lymphoma                                                                Targeted T-cell specificity, lysosomal escape
  Abraxane (Celgene)                         Albumin-bound paclitaxel                               Breast cancer, NSCLC, pancreatic cancer                                                  Greater solubility, increased delivery to tumor
  **Nanocrystal NPs**                                                                                                                                                                        
  Tricor (AbbVie)                            Fenofibrate                                            Hyperlipidemia                                                                           Increased bioavailability simplifies administration
  Vitoss (Stryker)                           Calcium phosphate                                      Bone substitute                                                                          Mimics bone structure
  Zanaflex (Acorda)                          Tizanidine HCl                                         Muscle relaxant                                                                          High drug loading and bioavailability
  Avinza (Pfizer)                            Morphine sulfate                                       Psychostimulant                                                                          High drug loading and bioavailability, ER
  EquivaBone (Zimmer Biomet)                 Hydroxyapatite                                         Bone substitute                                                                          Mimics bone structure
  Emend (Merck)                              Aprepitant                                             Antiemetic                                                                               Absorption and bioavailability increases
  Focalin (Novartis)                         Dexamethylphenidate HCl                                Psychostimulant                                                                          Higher drug loading and bioavailability
  Megace ES (Par Pharmaceuticals)            Megestrol acetate                                      Antianorexic                                                                             Lower dosing
  Invega Sustenna (Janssen)                  Paliperidone palmitate                                 Schizophrenia, schizoaffective disorder                                                  Slow release of injectable low-solubility drug
  NanOss (RTI Surgical)                      Hydroxyapatite                                         Bone substitute                                                                          Mimics bone structure
  Ostim (Heraeus Kulzer)                     Hydroxyapatite                                         Bone substitute                                                                          Mimics bone structure
  OsSatura (IsoTis Orthobiologics)           Hydroxyapatite                                         Bone substitute                                                                          Mimics bone structure
  Rapamune (Wyeth Pharmaceuticals)           Sirolimus                                              Immuno-suppressant                                                                       Better bioavailability
  Ritalin LA (Novartis)                      Methylphenidate HCl                                    Psychostimulant                                                                          Higher drug loading and bioavailability
  Ryanodex (Eagle Pharmaceuticals)           Dantrolene sodium                                      Malignant hypothermia                                                                    More rapid rate of administration at higher doses
  **Inorganic NPs**                                                                                                                                                                          
  Dexferrum (American Regent)                Iron dextran                                           Iron deficiency in CKD                                                                   Increased dose
  Feraheme (AMAG Pharmaceuticals)            Ferumoxytol                                            Iron deficiency in CKD                                                                   Prolonged, steady release with less frequent dosing
  Ferrlecit (Sanofi-Aventis)                 Sodium ferric gluconate complex in sucrose injection   Iron deficiency in CKD                                                                   Improved dose
  Infed (Actavis Pharma)                     Iron dextran                                           Iron deficiency in CKD                                                                   Improved dose
  Venofer (American Regent)                  Iron sucrose                                           Iron deficiency in CKD                                                                   Improved dose
  **Protein NPs**                                                                                                                                                                            
  Abraxane (Celgene)                         Albumin-bound paclitaxel                               Breast cancer, NSCLC, pancreatic cancer                                                  Better solubility, increased delivery to tumor sites
  Ontak (Eisai)                              Denileukin diftitox                                    Cutaneous T-cell lymphoma                                                                Targeted T-cell specificity, lysosomal escape

ALL, acute lymphoblastic leukemia; AMD, age-related macular degeneration; AML, acute myeloid leukemia; CKD, chronic kidney disease; ER, extended release; HCl, hydrochloride; IFN, interferon; NP, nanoparticle; NSCLC, non--small-cell lung cancer; SCID, severe combined immunodeficiency disease.

![Schematic presentation of various transportation pathways across BBB.](fnins-14-00494-g001){#F1}

1.  Safety, and high efficacy.

2.  Drug targeting to specific sites to reduce off target toxicity.

3.  Improved pharmacokinetic behavior by sustained drug release with wide safety margin.

Although it is quite difficult to say which nanoparticulate drug delivery system is having more potential and safe among listed nanocarriers such as polymers, micelles, liposomes, dendrimers, nanocrystals, SLNPs, the size, shape, composition, surface charge, monomers molar ratio, solubility of drug, their physiochemical properties and further their release in different acidic and basic environment inside cells, plays very important role in pharmacokinetics of each type of nanocarriers. [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} describes pharmacokinetics of each type of nanocarriers and their biocompatibility, respectively.

###### 

Different nanoformulations with their biopharmaceutical properties.

  Formulation type                            Drug name                 Route of administration   *in vivo* (Pharmacokinetics/Pharmacodynamics)                                            References
  ------------------------------------------- ------------------------- ------------------------- ---------------------------------------------------------------------------------------- -----------------
  **Nanocrystals**                                                                                                                                                                         
                                              Fenofibrate               Oral                      Enhanced oral bioavailability                                                            [@B60]
                                              Megestrol acetate         Oral                      Enhanced oral bioavailability                                                            [@B196]
                                              Nitrendipine              Oral                      Enhanced oral bioavailability and hepatoprotection                                       [@B222]
                                              Nobiletin                 Oral                      Enhanced oral bioavailability and rapid absorption                                       [@B139]
                                              Tranilast                 Pulmonary Oral            Better anti-inflammatory effects in lung Enhanced bioavailability and rapid absorption   [@B86]; [@B137]
                                              Carbendazim               Oral                      Enhanced oral bioavailability                                                            [@B72]
                                              Cilostazol                Oral                      Enhanced oral bioavailability                                                            [@B74]
                                              Curcumin                  Oral                      Improved oral bioavailability                                                            [@B140]
                                              Danazol                   Oral                      Improved oral bioavailability                                                            [@B221]
  **Solid lipid nanoparticles**                                                                                                                                                            
  Solid-in-oil nanosuspensions                Diclofenac Na             Dermal                    Improved percutaneous absorption                                                         [@B159]
  Lectin-modified solid lipid nanoparticles   Insulin                   Oral                      Superior oral bioavailability                                                            [@B233]
  Solid lipid nanoparticles                   Lidocaine                 Dermal                    Controlled dermal permeation and duration of action                                      [@B154]
  Solid lipid nanoparticles                   Azidothymidine            IV                        Improved permeability and brain retention                                                [@B169]
  Solid lipid nanoparticles                   Clozapine                 IV                        Improved systemic exposure, decreased clearance                                          [@B111]
  **Micelles**                                                                                                                                                                             
  Block copolymeric micelles                  Pilocarpine               Ocular                    Improved miotic activity                                                                 [@B118]
  Self-micellizing solid dispersion           Tranilast                 Oral                      Enhanced oral bioavailability                                                            [@B139]
  Block copolymeric micelles                  Camptothecin              IV                        Extended systemic exposure                                                               [@B215]
  Block copolymeric micelles                  Doxorubicin               IV                        Improved systemic exposure, decreased clearance                                          [@B158]
  Block copolymeric micelles                  Paclitaxel                                          Enhanced systemic exposure, decreased clearance                                          [@B84]
  **Polymeric nanoparticles**                                                                                                                                                              
  PLGA and alginate nanoparticles             Clotrimazole/econazole    Oral                      Enhanced oral bioavailability                                                            [@B147]
  PLA-PEG nanoparticles                       Docetaxel                 IV                        Extended half-life, enhanced antitumor effect                                            [@B65]
  PLGA nanoparticles                          Doxorubicin               IV, IP                    Extended half-life, Reduced distribution to heart                                        [@B169]
  PLGA nanoparticles                          Rifampicin                Oral                      Improved oral bioavailability                                                            [@B184]
  Chitosan analog nanoparticles               siRNA                     Oral                      Improved systemic distribution and gene silencing                                        [@B234]
  Albumin nanoparticles                       Paclitaxel                IV                        Low inter-/intrapatient variability, tumor targeting                                     
  Hydrogel nanoparticles                      Insulin                   Oral                      Improved oral bioavailability                                                            [@B29]
  PLGA nanoparticles                          Glucagon                  Pulmonary                 Extended half-life and enhanced bioavailability                                          [@B138]
  PLGA nanoparticles                          VIP derivative            Pulmonary                 Enhanced anti-inflammatory effects                                                       [@B141]
  Ethyl cellulose/casein nanoparticles        Celecoxib                 Oral                      Enhanced oral bioavailability                                                            [@B127]
  **Emulsion**                                                                                                                                                                             
  Self-emulsifying drug delivery system       Cinnarizine               Oral                      Improved oral bioavailability                                                            [@B102]
  Self-emulsifying drug delivery system       Coenzyme Q~10~            Oral                      Improved oral bioavailability                                                            [@B141]
  Self-emulsifying drug delivery system       Cyclosporin A             Oral                      Improved oral bioavailability                                                            [@B194]
  Self-emulsifying drug delivery system       Simvastatin               Oral                      Improved oral bioavailability                                                            [@B202]
  **Dendrimers**                                                                                                                                                                           
  Polylysine dendrimer                        Doxorubicin               IV                        Long-lasting systemic exposure, enhanced accumulation in tumor tissues                   [@B82]
  Poly (amidoamine) dendrimer                 Flurbiprofen              IV                        High distribution and retention in site of inflammation                                  [@B9]
  PEGylated polylysine dendrimer              Methotrexate              IV                        Prolonged systemic exposure                                                              [@B81]
  Lactoferrin-conjugated dendrimer            Methotrexate              IV                        Enhanced accumulation in lung                                                            [@B99]
  Poly (amidoamine) dendrimer                 Piroxam                   IV                        Extended systemic exposure                                                               [@B162]
  **Liposomes**                                                                                                                                                                            
  Liposome (PC/Chol)                          O-palmitoyl tilisolol     IV                        High distribution in neoplastic tissue                                                   [@B87]
  Liposome (PC/PG)                            Paclitaxel                IV                        Prolonged systemic exposure                                                              [@B46]
  Liposome (PC/Chol/10% DSPEPEG2000)          Prednisolone              IV                        Increased and prolonged systemic exposure                                                [@B200]
  Liposome (Phospholipid/Chol)                Amikacin                  IV                        Extended half-life of the drug in vitreous                                               [@B64]
  Liposome (PC/Chol/DSPG)                     Amphotericin B            IV                        Augmented systemic exposure, decreased RES uptake                                        [@B207]
  Liposome (DSPC/DSPG/Chol)                   Cytarabine/daunorubicin   IV                        Decreased clearance                                                                      [@B45]
  Liposome, PEGylated liposome                Doxorubicin               IV                        High distribution in neoplastic tissue                                                   [@B232]

RES, reticuloendothelial system; siRNA, small interfering ribonucleic acid; VIP, vasoactive intestinal peptide; IP, intraperitoneal; IV, intravenous; PC, phosphatidylcholine; PG, phosphatidylglycerol; Chol, cholesterol; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; DSPE,1,2-distearoyl-sn-glycero-3-phosphoethanolamine;DSPG,1,2-distearoyl-snglycero-3-phosphoglycerol; PEG, polyethylene glycol; PLA, polylactic acid; PLGA, poly (lactic-co-glycolic acid).

###### 

Biopharmaceutical and safety profile of nanoformulations ([@B142]).

  Biopharmaceutical properties                                                                 Safety                                                                                           
  -------------------------------------------------------------------------------------------- -------------------------------------------------------- --------------------------------------- -------------------------------------------------------------------------
  **Engineered Nanoparticles**                                                                                                                                                                  
  Improved systemic exposure High retention in mucosal layer Several dosage routes available   Low sustained releasing potency                          Decreased gastric irritancy of NSAIDs   Toxic risk due to high C~max~ cytotoxic potential
  **Lipid Nanosystems**                                                                                                                                                                         
  Biodegradable and metabolized Specific drug delivery Prolonged systemic exposure             Rapid clearance due to RES uptake Limited dosage route   Low toxicity Low antigenicity           Cytotoxicity depending on the surfactant used
  **Micelles**                                                                                                                                                                                  
  High membrane permeability High solubilizing potency Improved systemic exposure              Low sustained releasing potency                          Low immunogenicity                      Toxic risk due to high C~max~ Cytotoxicity depending on used surfactant
  **Polymeric Nanoparticles**                                                                                                                                                                   
  Stable *in vivo* drug release Long duration of action                                        Need to avoid initial burst Limited dosage route         Low immunogenicity                      Need to be removed surgically for non-degradable polymers
  **Dendrimers**                                                                                                                                                                                
  Controlled release High solubility Specific rug delivery                                     Limited dosage route                                     Low immunogenicity                      Hemototoxicity

Targeted delivery of the drug is a promising approach to minimize the side effects of a therapeutic agent. Nanocarrier based brain targeted delivery can be accomplished via receptor-mediated, transporter-mediated and pharmacological disruption of BBB. Decorating the delivery system with BBB receptor ligands, coupling antibodies, peptides or aptamers with BBB receptor ligand delivery system, and transporter ligands coupled micelle delivery are some of the approaches for nanocarriers based brain targeting ([@B59]; [@B51]). In the current review, we provide an overview of different nanoformulations of neuroprotective agents, with particular emphasis on their usefulness in different neurological diseases and the opportunities for future research.

Nano Approaches Toward CNS Drug Delivery {#S2}
========================================

Nanotechnology is an innovative, promising and cutting edge approach for delivering neurotherapeutics across BBB. In the last few decades, nanomedicines have shown great potential toward CNS drug delivery owing to its nanosize range, their unique physic-chemical properties and ability to exploit surface engineered biocompatible and biodegradable nanomaterials ([@B85]). Nanotechnology-based approaches for site-specific delivery of therapeutics and other compounds across the BBB may potentially be engineered to carry out particular functions as needed. The drug, the pharmacologically active component to be delivered, itself constitutes one part of the nanoengineered complex while remaining complex is intended to accomplish other key functions such as encapsulating the active drug protection against enzymatic degradation, drug release at specific pH, ability to cross the BBB, and targeting specific brain cells ([@B189]). A wide range of pharmaceutical nanocarriers including liposomes, PNPs, SLNs, micelles, dendrimers, and some others have been developed ([@B164]; [@B220]; [@B144]).

Micelles {#S2.SS1}
--------

Micelles, the vesicles which is made up of amphiphilic surfactants (non-polymeric micelles) or amphiphillic copolymers (polymeric micelles) have recently fascinated the researchers as a novel drug carrier system to the CNS ([@B5]; [@B208]). As compared to non-polymeric micelles, polymeric micelles are considered more stable having long duration of action and high biodistribution ([@B144]). They have a core-shell structural design with size ranging from 10 to 100 nm consisting outer hydrophilic environment mostly made up of polyethylene glycol (PEG) and inner hydrophobic core synthesized by means of molecules such as polycaprolactone, polypropylene glycols, phospholipids, and fatty acids, thus they allow loading of hydrophobic drugs ([@B208]). The external hydrophilic shell provides stability to micelles in an aqueous environment and prolongs their circulation time in bloodstream, thus protecting it from reticulo-endothelial system (RES) and further facilitate their accumulation in specific region having leaky vasculature ([@B152]). The class of pluronic (also known as Poloxamers) block copolymers is of particular interest as they have an ability to hinder drug efflux transporters, for instance, inhibition of P-gp efflux transporters widely expressed on BBB and enhance drug shipment to the CNS ([@B13]). Moreover, it was demonstrated that they facilitate the brain delivery of low molecular mass drugs incorporated into them by escalating the drug solubility and stability in plasma.

Number of attempts has been made to transform the micelles in such a way that enhanced concentration of loaded drug can cross on another side of BBB easily. One such modification is attaching either polyclonal antibodies against brain-specific antigen, α2-glycoprotein, or insulin to target the receptor at the luminal side of BBB. In mice, the intravenous administration of these modified micelles after loading with a fluorescent dye or neuroleptic drug haloperidol, resulted in improved delivery of the fluorescent dye to the brain and drastic increase in the neuroleptic effect of haloperidol ([@B78]).

Another modification of the micelle system is direct conjugation of the drug molecule and targeting moiety to the amphiphilic segment. For instance, [@B234] studied transferrin-modified cyclo-(Arg-Gly-Asp-d-Phe-Lys)-Paclitaxel conjugate-loaded micelle and demonstrated the increased uptake by the brain microvascular endothelial cells *in vitro* in addition to the lengthened retention in glioma tumor *in vivo* and no considerable toxicity was noticed. Poly lactic-glycolic acid (PLGA) nanoparticles (NPs) coated with Chitosan oleate (CS-OA) which imparts positive surface charge and Chitosan Oleate Self-Assembled Polymeric Micelles based nanosystems were prepared and compared, for their interaction with cells i.e., Caco-2 and Hela cells. micelles and PLGA NPs, loaded with lipophillic model drug i.e., resveratrol, based on release profiles, TGA analysis and the cell line interaction results PLGA-CS-OA found to be more stable compared with polymeric micelles ([@B122]).

Liposomes {#S2.SS2}
---------

Liposomes are considered as the first generation of the novel colloidal nanocarriers which were successfully proven themselves as a drug carrier system in the 70's ([@B14]). These are small spherical vesicles composed of the hydrophilic compartment at the center enclosed by a single or multiple phospholipid bilayers due to which they morphologically resemble with the cell membrane and are used as a strategic approach for drug delivery, proteins and peptides ([@B116]; [@B220]; [@B144]). They can be classified into three categories depending upon their size and number of bilayers: small unilamellar (10--50 nm), large unilamellar (50--1000 nm), and multilamellar (20--100 nm). These are reversible structures due to presence of non-covalent interactions such as van der walls forces and hydrogen bonding between molecules ([@B165]).

Unmodified conventional liposomes have short circulation time in the body as they are quickly eliminated from the systemic circulation by the cells of RES and therefore various attempts have been made to develop long-circulating and targeted liposomes ([@B131]). Among such attempts, polyethylene glycol (PEG) coating on liposomes is a successful attempt to avoid RES recognition of nanocarrier system ([@B11]; [@B220]). Targeted delivery of PEG-modified liposomes to the brain can be facilitated by further modifications with various ligands like monoclonal antibodies (mAbs) against glial fibrillary acidic proteins, transferrin receptors (TRs) or human insulin receptors ([@B148]; [@B183]). Transferrin-conjugated liposomes have been demonstrated to preferentially deliver the payload like 5-fluorouracil to the brain facilitated by receptor-mediated endocytosis ([@B192]). Conjugation of prednisolone-loaded liposomes with mAbs that will be recognized by cell surface receptors in the targeted tissue called immunoliposomes, demonstrated further improvement in distribution of liposomes inside brain and high efficacy against experimental autoimmune encephalomyelitis ([@B181]). Immunoliposomes as nanocarrier systems for brain drug delivery also have some usage in gene therapy as demonstrated by TRsMAbs-targeted liposome conjugated with a plasmid for tyrosine hydroxylase in treating PD in a rat model ([@B240]). This approach has also been used for delivery of small interfering RNA (siRNA) against epithelial growth factor receptor (EGFR) and demonstrated the knock-down of EGFR expression and increased survival of mice implanted intracranially with brain tumors ([@B149]). Another approach to improve the efficiency of liposomes in crossing the barriers and increase therapeutic success is their modifications with cell penetrating peptides (CPP). For instance, specific ligand transferrin (T7) and non-specific cell penetrating peptide (TAT) conjugated doxorubicin encapsulated liposomes demonstrated high availability across BBB and specific cell targeting to the brain glioma ([@B239]). Recently nimodipine proliposomes, which form liposomal structure upon contact with water, augment the oral bioavailability of the drug ([@B195]). In another study, compounds like α-tocopherol (Toc) and omega3 fatty acid were loaded into liposomes with anti-Alzheimer drug tacrine for the treatment of AD with intranasal route ([@B32]).

Polymeric Nanoparticles {#S2.SS3}
-----------------------

Polymeric nanoparticles are solid colloidal dispersion of biodegradable and biocompatible polymers such as poly (alkylcyanoacrylate) (PACA), polyesters such as poly (lactide) (PLA), poly (D,L-lactide-co-glycolic acid) (PLGA), and several others such as natural proteins and polysaccharides with size range 10--100 nm ([@B97]). They consists a core of dense polymer matrix to encapsulate the lipophillic drugs and a hydrophilic corona to provide steric stability to NPs. The drug to be delivered may be encapsulated, adsorbed or chemically linked to the surface of the NPs ([@B174]). The residence time of these NPs in systemic circulation can be increased by the surface modification either with physical adsorption or covalent binding of hydrophilic polymers such as PEGs and polysaccharides, whereas the inclusion of tissue-specific ligands facilitates targeted delivery to the brain ([@B125]; [@B216]). It has been established that coating of poly (n-butylcyanoacrilate) (PBCA) NPs with 1% polysorbate 80 (PS80) amplified the concentration of rivastigmine or tacrine drug inside the brain as compared with free drug and selectively targeted to the CNS for AD reducing the hepatic or gastrointestinal side-effects coupled with conventional treatment approach ([@B216]). Another study proved that dalargin containing PS80-coated PACA nanoparticles was capable to cross the BBB and produce its antinociceptive effect, after oral administration ([@B35]). A possible mechanism of such delivery is adsorption of PS80-coated PACA nanoparticles on ApoE and B from the bloodstream upon intravenous injection followed by transcytosis across BBB using the low-density lipoprotein receptors ([@B94]). PLGA nanoparticles exhibits good carrier for delivering drugs across BBB. *In vivo* distribution of vanlafaxine loaded PLGA nanoparticles against depression was tested in C57/bl6 mice and in *vitro* BBB model using hCMEC/D3 cell. They observed that transferring receptor mediated PLGA nanoparticles have better biodistribution in brain via intranasal administration and not affected by P-gP pump efflux enhacing functionalized nanoparticles concentration in the basolateral side after 24 h via receptor mediated endocytosis ([@B24]).

Solid-Lipid Nanoparticles {#S2.SS4}
-------------------------

Solid-lipid nanoparticles (SLNs) are attracting major attention as novel drug carriers nowadays and are at the forefront of the rapidly emerging nano-delivery system ([@B95]). These are aqueous colloidal nanocarriers system which are composed of physiological lipid (triglycerides, fatty acids, steroids, and waxes, etc.), dispersed in water or in an aqueous surfactant solution and possess the ability to get solidify upon cooling ([@B10]; [@B129]). A number of efforts have been made to increase the drug loading capacity and long-term stability of SLNs, one such effort being the development of nanostructured lipid carriers (NLCs) by amalgamation of spatially dissimilar lipids or blending solid lipids with liquid lipids. Modification of SLNs with PEG increases penetration to BBB and enhances drug delivery to the CNS as demonstrated by a comparative study of SLNs and PEG-modified SLNs loaded with antitumor drugs like camptothecin and doxorubicin ([@B17]; [@B219]). SLNs are preferred more over PNPs due to numerous advantages such as low intrinsic cytotoxicity, physical stability, shielding of labile drugs from degradation, controlled release which provide them potentiality to be used as a brain drug delivery system, especially for brain tumors ([@B101]). The possible mechanism of their delivery across BBB may be endocytosis, transcytosis which takes place in the endothelial cells lining the blood capillaries in brain or permeation through the tight junctions between endothelial cells. Furthermore, the adsorption of a plasmatic protein such as the apolipoprotein E, onto SLNs surface could facilitate its uptake into brain mediated by adherence to the endothelial cells of the BBB ([@B95]; [@B168]; [@B17]). The above approach has been used for the encapsulation of a broad range of drugs to achieve target-specific delivery of drugs across BBB. Sterylamine-based SLNs containing clozapine, an antipsychotic drug have been fabricated and demonstrated to deliver the drug successfully inside the brain after intravenous and intraduodenal administration ([@B111]). Other examples of drug loaded SLNs include quercetin loaded SLNs to treat AD ([@B37]), atazanavir loaded SLNs for treatment of HIV-encephalitis ([@B28]). Recently, it was observed that riluzole-loaded SLNs have greater efficacy than free riluzole in amyotrophic lateral sclerosis (ALS) rat model developed by immunization using the experimental allergic encephalomyelitis ([@B19]).

Nanoemulsions {#S2.SS5}
-------------

Nanoemulsions are either oil-in-water (O/W) or water-in-oil (W/O) colloidal particulate systems that are composed of edible oils, surface-active agents (surfactants) and water, having a size range 100--500 nm ([@B179]; [@B109]). Recently, their use as drug delivery system has been promoted heavily to tackle several problems associated with conventional delivery systems such as low bioavailability, poor targetability, and penetrability across BBB ([@B109]). Various oils and surface modifiers that are used in preparation are the key determinants of the versatility of nanoemulsions ([@B179]). For instance, fabrication of nanoemulsions with oils that are rich in omega-3 polyunsaturated fatty acids (PUFA) imparts specific properties to nanocarriers for overcoming biological barrier, including the BBB, therefore help in achieving the rapid distribution of drugs to peripheral sites, especially the brain ([@B183]). The nanoemulsion system containing pine-nut oil significantly increased the oral bioavailability of paclitaxel ([@B204]).

Dendrimers {#S2.SS6}
----------

Dendrimers are the emerging polymeric structures that are known for their defined structures, and versatility in drug delivery. They have 3-D symmetrical architecture possessing an inner core from which a number of hyper-branches, known as "generations," having various chemical functional groups at the peripheral terminal surface arise due to which they can be easily functionalized with different ligands ([@B209]; [@B224]; [@B103]; [@B38]). Depending upon the generations, complexity and building block materials, a wide range of dendrimers has been developed among which polyamidoamine (PAMAM), polypropylene imine (PPI), and polylysine dendrimers are of intense interest for both hydrophobic and hydrophilic drug molecules delivery. The high molecular weight hydrophilic/hydrophobic entities either physically entrap/conjugate by host-guest interactions or covalently bound with peripheral functional groups of dendrimers to form a dendrimer-drug complex ([@B209]). Although, dendrimers have wide application in drug delivery, yet their use in biological systems is limited due to complex synthetic procedures and toxicity issues ([@B81]; [@B209]).

Nowadays, as a drug carrier, dendrimers are given more preference over traditional polymers due to various features such as high aqueous solubility, biocompatibility, polyvalency, and precise molecular weight which make them amenable for targeted drug delivery in the brain ([@B42]; [@B206]). They have shown potential as carriers of drugs, therapeutic nucleic acids, peptides and proteins, contrast agents for CNS disorders treatment, imaging, and diagnosis ([@B225]; [Figure 3](#F3){ref-type="fig"}). [@B8] synthesized Poly (propylene imine) dendrimers core and maltose-histidine shell (G4HisMal) and check their biocompatibility and ability to penetrate BBB, they were tested it against AD and found their high ability to cross BBB with significant biocompatibility showing memory protection in transgenic mice model of Alzheimer disease via synapse protection. The *in vitro* efficacy and *in vivo* targeting capability of hydroxyl-G6 PAMAM dendrimer--9-amino-minocycline conjugate (D-mino) was checked, additionally D-mino was assessed for anti-inflammatory and antioxidant activity in lipopolysaccharides-activated murine microglial cells. The rapid uptake, decreases inflammatory cytokines and nitric oxide levels suggested that dendrimers formulation are having high efficacy as compare to free drug, further it was observed that fluorescently labeled dendrimer conjugate (Cy5--D-mino) crosses the blood brain barrier much efficiently than free drug ([@B186]; [Figure 4](#F4){ref-type="fig"}).

![Nanotechnology-based various CNS delivery systems.](fnins-14-00494-g002){#F2}

![Mechanism of nanotherapeutics, such as methotrexate and doxorubicin, delivery by dendrimers for brain tumor. Reproduced with permission from [@B224]. Copyright @ 2014, American Chemical Society.](fnins-14-00494-g003){#F3}

![*In vivo* cellular localization of Cy5-D-mino. The endotoxin kits with Cerebral Palsy (*n* = 3) received Cy5-Dmino (55 mg/kg, i.v) on Post Natal Day 1 and sacrificed 24 h post-injection. Brain slices contain Cy5-D-mino (magenta) were co-stained with GFAP (astrocyte marker, green)/IBA1 (microglial marker, red)/DAPI (blue). Cy5-D-mino is mainly co-localized with activated microglia at the corpus callosum and angle of lateral ventricle. The images on the right panels are the higher magnification of the region of interest marked with the boxes on the left panels. Reproduced with permission from [@B186]. Copyright @ 2017, American Chemical Society.](fnins-14-00494-g004){#F4}

Targeted delivery by dendrimers can be achieve by attaching target ligands such as transferrin family ligands having an affinity for TRs, mAbs against specific receptors, lectins such as wheat germ agglutinin (WGA), etc ([@B206]). The dendritic approach has been applied to improve the solubility and oral absorption of various drugs such as camptothecin (CPT), by conjugating drugs with PAMAM dendrimers ([@B173]). Recently, it was demonstrated that cisaconityl linkage, an acid-sensitive linkage, in PAMAM-PEG-Doxorubicin (DOX) conjugates followed an acid-triggered release kinetics which gradually increases with increasing degree of PEGylation and simultaneously imparts following properties to the conjugates: reduced hepatic and splenic accumulation, prolonged circulation time, and enhanced tumor buildup of the conjugates ([@B237], [@B238]).

Mechanism of Action of Drug Release {#S3}
===================================

The physiochemical properties of drug loaded nanocarrier like hydrophilicity, surface charge and targeting ligands of nano carrier is the deciding factor for the adsorption on the brain capillary endothelial cells. Surface charge like positive nature of the nanomaterials interacts with the negative surface charge of endothelial cells of brain, due to electrostatic interactions between carrier and cells, secondly lipophillic nature of nanocarriers also enhance and facilitates adsorption process ([@B114]; [@B106]). These approaches reduces the clearance of nanocarrier by the fixed macrophages of the mononuclear phagocytic system (MPS), Once, the nanomaterials get absorbs either through targeting low density lipoprotein receptors present on the microvessel brain capillary endothelial cells ([@B90]) by means of normal endocytosis and transcytosis, desorption occurs and reenter into the blood stream, where drug loaded nanocarrier releases its encapsulated or adsorbed drug on the surface of blood brain barrier and further diffuses into brain parenchyma. The average size of human cells is 10--20 μm, where as the minimal diameter of blood capillaries are 6--9 μm, due to their nano size ranges nanomaterials get easily transported and internalizes by brain capillary endothelial cells via endocytosis and transcytosis mechanism of transport ([@B212]). The adsorbed drug--carrier conjugates is endocytosized by the cells, at times followed by exocytosis, and further penetration of the nano carrier into the cells or brain parenchyma occurs.

The mechanism of drug delivery by nanotechnology is not still well-explored, however, various suggestions have been put forward to suggest possible mechanisms. Though the uptake of nanocarriers along with drugs into the brain has been proposed to occur by following six mechanisms ([@B93], [@B94]; [@B218]):

1.  Increased transport across the endothelial cell layer facilitated by higher concentration gradient due to increased retention of the nanocarriers in the brain blood capillaries with an adsorption to the capillary walls. Since the diffusing drug can be effluxes out by various transporters such as P-gp, it is not a good mechanism to achieve a sufficient amount of drug inside the brain to elicit a relevant pharmacological response.

2.  Inhibition of the efflux system particularly P-gp.

3.  Toxicity to the brain vasculature.

4.  Solubilization of the endothelial cell membrane lipids due to general surfactant effect followed by membrane fluidization and enhanced drug permeability across the BBB.

5.  Permeation of nanocarrier system through the tight junctions after the opening of them.

6.  Endocytosis and transcytosis phenomenon through the endothelial cell layer.

Since the entry of foreign entities in CNS is strictly prohibited by BBB, only selective one gets access to the brain. They get entry into the brain either by passive, gradient-dependent (passive targeting) or active, energy-dependent (active targeting) pathways. As the passive movement of water solutes through the clefts between adjacent cells (paracellular transport) is negligible at physiological conditions due to the presence of tight junctions as well as the early phases of neurological disease do not involve any defects in BBB to allow drug transport, implication of this transportation pathway for delivery of drug-loaded nanocarrier is not a successful approach. As an alternative, consideration should be given to the transportation of nanocarriers per se through the endothelial cells (transcellular transport). The nanocarriers of size less than 500 Da having the ability to absorb inside cells are suitable for transcellular transportation ([@B56]). Transcytosis process especially the receptor-mediated transcytosis across BBB is an attractive strategy to deliver drugs into CNS. It requires vector for the delivery of nanocarrier between the apical and basolateral surface in polarized cells. Receptor-mediated internalization of cargo followed by vesicular transport is a suitable option as nano-delivery systems of size 100--200 nm range can be easily accommodated in these transport vesicles. Three distinct steps are involved in overall transcytosis process: endocytosis of the nanocarrier at the plasma membrane, trafficking of intracellular vesicles toward the opposite surface followed by exocytosis ([@B166]; [@B150]; [@B56]).

Internalization via phagocytic mechanism occurs by various pathways among which clathrin-dependent and caveolin-dependent pathways are the major one:

1.  Clathrin-mediated endocytosis happens in all mammalian cells. As the nanocarrier binds with a specific receptor on the cell membrane, it triggers the polymerization of clathrin-1, a cytosolic protein underneath the plasma membrane forming an inward budding leading to the internalization of cargo ([@B166]). After wrapping of the nano-delivery system, the GTPase activity of dynamin pinches off the inward budding resulting into the formation of clathrin-coated vesicles ([@B163]). The clathrin coat shed off during the movement of vesicles inside cytosol with the help of energy provided by actin, leading to the formation of early endosomes as detected by early endosome antigen-1 (EEA-1), a typical marker. The early endosome delivers their content to late endosomes and finally to the lysosomes where it is degraded off. The compartmental pH gradually falls during the transition of late endosomes to the lysosomes, which triggers the release of drug from nano-vehicle and eventually the drug is released at the desired site ([@B121]; [@B56]).

2.  Another well known pathway for delivery of nanocarriers inside the brain is caveolar pathway. This pathway is similar to the clathrin-mediated pathway in most of the aspects but there is possibility to escape lysosomal delivery which is a key factor that makes it different from the clathrin-mediated pathway ([@B119]). For the same difference, this pathway augments the delivery of drugs at the targeted site and therefore improve the therapeutic value of drugs, thus targeting receptors associated with caveolae may prove good approach for transcellular delivery of the nanocarriers. Caveolae are flask-shaped plasma membrane invaginations and caveolin protein, present in three isoforms in mammalian cells: caveolin-1, caveolin-2, and caveolin-3 play a dominating role in this transportation pathway ([@B92]). As soon as the nanocarriers binds to the caveolar receptor, it is internalized forming a vesicular structure known as cavicle, by the involvement of dynamin in a similar way as in clathrin-mediated pathway. The cavicle moves inside the cytosol with the help of energy derived from actin and get fused with caveosomes which have neutral pH and then head toward the endoplasmic reticulum (ER). It is considered that nanocarrier from ER penetrates into the cytosol and finally gain access to the nucleus through the nuclear pore complex ([@B83]; [@B153]; [@B92]).

Applications of Nanotechnology in CNS Disorders {#S4}
===============================================

Nanotechnology has revolutionized the field of treating various neurological disorders and has provided a number of new approaches that have shown potential for treating neurodegenerative disorders like AD, PD, stroke, epilepsy, HD, and brain tumor. Molecules are nano-engineered so that they have an ability to traverse the BBB, target the specific cell or signaling pathway, act as a carrier for gene delivery. Besides delivery of therapeutic drugs, nanotechnology has also gained the interest of researchers for delivery of radiocontrast agents, imaging agents for diagnosis purpose. [Figure 5](#F5){ref-type="fig"}, is the schematic representation of nanotechnology-based therapy for CNS disorders depicted that when an external stumuli or in diseased conditions glial activation occurs which leads to neuroinflammation and leads to imbalance between pro-inflammatory and (IL-1β, TNF-α, and IL-6) and anti-inflammatory cytokines (IL-4, IL-10, etc.), here the authors are showing through schematic representation that drugs loaded with nanoformulations such as immunoliposomes, dendrimers, micelles, liposomes, and nanoparticles due to their small size and specific targeting ability stabilizes and modulate the release of drugs to cross the blood brain barrier and restores the healthy conditions via reducing neuroinflammation and glial cells activation.

![Schematic representation of nanotechnology-based therapy for CNS disorders.](fnins-14-00494-g005){#F5}

Alzheimer's Disease {#S4.SS1}
-------------------

Alzheimer's disease is a slowly progressive neurodegenerative disorder, and is the main culprit for dementia syndrome. Pieces of evidence state that its incidence and prevalence rate is more common in elder persons ([@B191]). Amyloid-β plaques and Tau protein hyper-phosphorylation are considered as hallmarks of AD ([@B96]). The degeneration of nervous tissue in AD starts years back of the actual appearance of the symptoms of the disease. The conventional treatment approaches are not able for complete treatment of disease, thus the inability of orally administered drugs such as tacrine, rivastigmine, etc. to treat the disease, opens the door for the application of nanotechnology for AD treatment.

A wide range of nano-formulations has been fabricated to have a beneficial impact on AD patients. It was demonstrated that PEG stabilized nanomicelles composed of phospholipids inhibit Aβ aggregation and attenuate Aβ-induced neurotoxicity in SHSY-5Y human neuroblastoma cell line *in vitro* ([@B145]). The *in vitro* study demonstrated the ability of phytochemical curcumin to reduce Aβ oligomerization and cytotoxicity, but poor bioavailability was shown when injected into mice ([@B226]). The nanoliposomal formulation of curcumin enhanced its bioavailability without disturbing its ability of inhibiting Aβ aggregation ([@B199]).

Since the increased level of metal ions, such as copper, also contributes in the pathology of AD, use of chelating agents is another approach for AD management ([@B108]). Microemulsion nanoparticles loaded with copper chelator d-penicillamine were found to have capability of crossing the BBB and dissolving the pre-existing Aβ aggregates *in vitro* ([@B34]).

Oxidative damage, another key factor in the pathology of AD, suggests the applications of antioxidants in AD management. Fullerene derivatives, the potent free-radical scavengers, have been found to possess neuroprotective action against glutamate receptors induced excitotoxicity. On the other hand ability of fullerene for neuroprotection, *in vitro* as well as *in vivo*, against Aβ toxicity has not been proved, yet its ability to inhibit Aβ peptide fibrillization and prevention of Aβ-induced cognitive impairments after intraventricular administration suggests its beneficial role in AD treatment ([@B160]).

Marked deficiency of acetylcholine (ACh) neurotransmitter is another important feature in the pathology of AD. Due to its faster decomposition in blood, the direct injection of free ACh is not effective for reversal of the imbalance in ACh. Thus, nanotechnological approach has been used for delivery of ACh in the brain to achieve balanced ACh level. The ACh loaded in carbon nanotubes have been found to restore the significant cognitive functions to pre-AD level in a kainic-acid induced mouse model as compared to free ACh ([@B227]).

Parkinson's Disease {#S4.SS2}
-------------------

Parkinson's disease, illustrated by loss of dopaminergic neurons in the substantia nigra of the midbrain and the generation of α-synuclein aggregates (Lewy bodies), is the next most common neurodegenerative disorder worldwide after AD. Nowadays, it is considered that pathology of PD is not just limited to a particular part of the brain but it involves various other regions of the brain, neurotransmitters such as imbalance in ACh and dopamine, and protein aggregates other than Lewy bodies ([@B80]). The manifestations of PD involve motor symptoms like tremor, speech, writing changes and non-motor symptoms like cognitive, behavioral, and autonomic changes.

The current medication treatments available for PD do not cure nor alleviate the progression of the disease but aim to provide the symptomatic relief to the patients, and beside this, the inability of available drugs to cross BBB is another challenge for treating PD. As a result, development of innovative and more effective therapy is the need of hour. This problem can be addressed by the nanotechnological approach, as it has shown great potential to reverse or limit the disease states, promote the functional regeneration of damaged neurons, provide neuroprotection and facilitate the delivery of drugs overcoming the BBB ([@B124]; [@B193]).

Gene delivery approach has been intensely exploited in the perspective of PD. The conventional gene delivery studies involve viral vectors, but they were commonly associated with toxicity and immunogenicity problems while nanotechnological approach was found to be devoid of such type of problems ([@B217]). The PEG and polyethyleimine nanogels complexes with antisense oligonucleotides demonstrated the efficient crossing of BBB *in vitro* and also delivered the oligonucleotides to the brain, when injected intravenously, more efficaciously particularly when the gels were functionalized with insulin or Tf molecules ([@B213]). In another study on 6-hydroxydopamine (6-OHDA) model of PD in rats, the striatal tyrosine hydroxylase enzyme activity was restored with reversal of motor impairment, after a single intravenous administration of tyrosine hydroxylase-encoding plasmids and Tf receptor antibody conjugated PEGylated liposomes ([@B235]). Recent study has confirmed that nerve growth factor (NGF) bound PBCA nanoparticles ([@B98]) and L-Dopa encapsulated nanoparticles cross BBB and alleviate basic symptoms of PD ([@B126]).

mPEG PLGA nanoparticles of size range 70 nm i.e., Schisantherin A (SA) was used against Parkinson diseases (PD) in zebrafish larvae where SA encapsuled in nanoparticles formulation that extended SA circulation in the blood stream and consequently an increased brain uptake and reported as potentially efficacious for the treatment of PD. It was found that nanoparticulate delivery of SA was much more effective than SA suspension alone. In addition, the SA-NPs exerted strong neuroprotective effects in zebrafish and cell culture model of PD ([@B31]).

Huntington Disease {#S4.SS3}
------------------

Huntington disease (HD) is described by preferential loss of neurons in striatum and other brain regions leading to progressive motor, cognitive, and psychiatric manifestations. It occurs due to monogenic mutation in the exon 1 of huntingtin gene which leads to polyglutamine (poly Q) expansion and causes misfolding and aggregation of huntingtin protein (HTT) in the brain ([@B12]). Several studies confirm the involvement of astrocytes in HD. Brains of HD patients and mouse models of HD demonstrates accumulation of mutant HTT in striatal astrocytes which ultimately leads to age-dependent HD-like pathology and premature mortality ([@B21]). Symptomatic and protective treatment strategies are available for HD but none of them are efficacious to completely cure the disease. Currently, tetrabenazine is FDA approved drug for the symptomatic treatment of HD.

A possible linkage between oxidative stress and neurodegenerative disorders such as HD has been shown in literature ([@B89]; [@B107]). Therefore, antioxidant therapy can be employed in HD to prevent oxidative stress. Fullerenols have ability to clear free radicals and reduce oxidative burden to cell. Jin et al reported their antagonistic behavior on glutamate receptors and therefore they can be implicated for neuroprotective use ([@B73]).

Nitrendipine is a calcium channel blocker that declines the incidences of dementia (upto 50%) in HD in a period of 2 years. Being hydrophilic, this drug has permeability issues and thus poorly crosses BBB. In a study, SLNs of nitrendipine were prepared and a comparison in the uptake of bulk drug and nanoformulation was done. The results demonstrated the higher uptake of drug when it was encapsulated in SLNs ([@B112]). In another study, short-interfering RNA (siRNA) encapsulated cyclodextrin nanoparticles were found capable to reduce expression of HTT mRNA both *in vivo* as well as *in vitro* ([@B58]).

Multiple Sclerosis {#S4.SS4}
------------------

Multiple sclerosis (MS) is a progressive autoimmune and inflammatory disease. It is a multifactorial disease in which body's immune cells attack on the nervous system. It involves various pathogenic mechanisms leading to demyelination of myelinated axons which results into slow conduction of nerve signal. There are evidences which suggest mutual interplay of microglial, astrocyte and T-cells beside demyelination ([@B88]; [@B136]). It is diagnosed on the basis of clinical findings, magnetic resonance imaging (MRI) and examination of Cerebrospinal fluid (CSF) ([@B88]). The prevalence rate of MS ranges 2--150 per 100,000 people and females are more susceptible than males ([@B76]). MS attack disrupt BBB in the section of brain or spinal cord from where peripheral T lymphocytes gain access to brain and attack the myelin gradually leading to demyelination ([@B231]).

In past few years, advancements in nanotechnology have shown promising outcomes in diagnosis and treatment of MS. The theranostic approach has been found to possess potential applications in the field of medical care and cure of MS ([@B190]). The interaction of carbon nanotubes with stem cell provides new opportunities in nerve tissue engineering to explore and add to cell behavior ([@B67]). It provides alternative ways to treat MS pathology related to non-genetic manipulations of signaling pathways *in vivo* ([@B135]). In a preclinical study, ciliary neurotrophic factor (CNTF) loaded microcapsules demonstrated *in situ* sustained delivery of CNTF upon encapsulation into polymers. This formulation was found to be devoid of any immune response and cytotoxic effect ([@B1]).

Beside role in therapeutics, nano-based approach also has implications in diagnosis of MS. DNA-carrier gold NPs based barcode assay is highly sensitive assay to detect biomarkers in CSF or diseased brain. Since radio diagnosis is a gold technique for detection of MS, this diagnostic assay may be highly useful in diagnosis of MS ([@B55]). All the recent developments made in nanotechnology opens a new door for diagnosis and treatment of MS pathologies.

Tumor {#S4.SS5}
-----

Brain tumors, like other body parts tumors, may be benign, originating and residing within the brain, or metastatic, originating from a tumor outside the CNS, among which glioblastoma multiforme (GBM) -- a malignant glioma, is the most prevalent. They are among the most challenging disease to treat due to poor prognosis, diagnosis, high recurrence rate, and availability of limited number of convenient methods to transport anti-cancer drugs across BBB in effective concentration ([@B177]; [@B143]). Current treatments available are just palliative, involving united approaches of surgical debulking with radiotherapy and chemotherapy, which are not sufficient for the complete treatment, and also the reversal to the tumor state again is most common ([@B143]). The inability of conventional methods has provided a platform for the development of innovative nanotechnological approach as a novel imaging tool or to improve anticancer drug delivery into tumors while minimizing its distribution and toxicity in healthy tissues ([@B16]).

Owing to the ability of glioma cells to aggressively infiltrate normal brain tissue and survive from the exposure to current adjuvant therapies, it is extremely important to construct specific targeted nanoplatforms capable of delivering imaging agents directly into invasive tumor cells. Owing to the ability of glioma cells to aggressively infiltrate normal brain tissue and survive from the exposure to current adjuvant therapies, it is extremely important to construct specific targeted nanoplatforms capable of delivering imaging agents directly into invasive tumor cells. Owing to the ability of glioma cells to aggressively infiltrate normal brain tissue and survive from the exposure to current adjuvant therapies, it is extremely important to construct specific targeted nanoplatforms capable of delivering imaging agents directly into invasive tumor cells.

Ability of glioma cells to infiltrate normal brain tissue and survive from the current adjuvant therapies opens the new door for employment of nano-based approach to deal with the glioma. Many researchers are trying to develop new nanotherapeutics approach to achieve a breakthrough in the treatment of gliomas. A broad range of nano-formulations for effective delivery of drugs across BBB has been developed and investigated ([@B104]). Such nanoformulations include PBCA nanoparticles loaded with methotrexate ([@B52]) and temozolamide ([@B203]), and have resulted in significantly increased intracerebral drug concentration as compared with free drugs. Similarly, the SLNs of etoposide ([@B100]) and paclitaxel ([@B54]), *in vitro*, demonstrated the enhanced inhibitory effect on proliferation of glioma cell lines more efficiently than the free drug alone. Dendrimers have also been used to deliver antineoplastic treatments to the brain. Methotrexate conjugated to polyether-copolyester (PEPE) dendrimers demonstrated improved cytotoxicity against U87 and U343 cancer cell lines in culture and this nanoformulation was able to overcome acquired resistance to the drug, suggesting its role in combating resistance to the drug in gliomas ([@B36]). Doxorubicin (DOX) loaded PEGylated PAMAM dendrimers demonstrated an extended therapeutic window by hindering C6 glioma spheroid proliferation and exhibited little cytotoxicity against brain microvascular endothelial cells *in vitro* ([@B62]). For imaging purpose, NPs as contrast agents offer detailed cellular and molecular imaging and thus provide information for efficient surgical removal of gliomas. Ultra small (less than 5 nm in diameter) gadolinium oxide crystals have been successfully used to label glioma cells GL-261 *in vivo* ([@B63]).

In a study, scientists encapsulated an antineoplastic drug in PEG-coated hexadecyl cyanoacrylate NPs and used against glioma. They observed controlled drug release kinetics along with higher diffusion of drug across BBB as compared to bulk drug in a rat model of gliosarcoma ([@B22]). In an another study, epidermal growth factor receptors (EGFRs)-targeted therapy explored for treatment of glioma where angiopep-2 (A2)-modified cationic lipid-poly (lactic-co-glycolic acid) (PLGA) nanoparticle (A2-N) loaded Gefitinib (Ge), an EGFR tyrosine kinase inhibitor (TKI) and Golgi phosphoprotein 3 (GOLPH3)-siRNA were prepared. They demonstrated that Angiopep-2-modified cationic lipid polymer crosses the BBB. Gefitinib can inhibit EGFR signaling and block the autophosphorylation of critical tyrosine residues on EGFR whereas GOLPH3 siRNA downregulate GLOPH3 expression ([@B228]).

Epilepsy {#S4.SS6}
--------

Epilepsy, a CNS disorder, is characterized by an abnormal increase in brain electrical activity that may be either limited to the focal area or spread throughout the brain, resulting in partial or generalized seizures, respectively ([@B69]). The current treatment methods, having the aim of diminishing the seizure frequency and severity while producing the minimum toxic effects to the brain and other tissues of the body, are almost failures due to various hurdles, such as the inability of drugs to cross BBB, drug resistance and recurrence of disease after drug discontinuation. Various strategies such as nano-based approach, prodrugs, efflux pump inhibition, opening of BBB by hyperosmolar solution, direct drug delivery to the ventricles and cortex, gene therapy, have been developed for epilepsy treatment, but among these all, the nano-technological approach has shown great potential for overcoming all the major hurdles in epilepsy treatment including, crossing of BBB and targeted delivering of drugs at their therapeutic concentration ([@B15]).

Solid lipid nanoparticles loaded with carbamazepine ([@B176]) and PLGA nanoparticles loaded with β-carotene ([@B230]) have been found to show more potential for anticonvulsant effect than nanoemulged loaded carbamazepine and polysorbate-80 coated PLGA nanoparticles, respectively. In a rat model, liposomal muscimol formulation ([@B91]) has been reported to suppress focal seizures while producing minimal histological alterations, and amiloride loaded liposomes ([@B4]) demonstrated higher anticonvulsant potential in comparison to the free drug in a mice model. In another study on a rat model, it was found that the subcutaneous administration of the ethosuximide loaded chitosan nanocapsules decrease the spike wave discharge. Because of their ability to provide stable release of the drug, these nano-formulations can be fabricated as depot drug delivery systems for long-term use of antiepileptic drugs ([@B66]).

Stroke {#S4.SS7}
------

Stroke, an acute CNS disorder, is characterized by the disruption to the vasculature supplying the brain, resulting into sudden symptoms, within seconds to hours, which usually depends on the fraction of the brain involved and the severity. There are two main types of stroke: Ischemic stroke, contributing 87% of total stroke, comprising of lacunar, cardioembolic and cryptogenic stroke, and the hemorrhagic stroke, having 13% contribution to the total stroke, comprising of 10% intracerebral and 3% hemorrhagic stroke ([@B172]). It is among the principal cause of mortality and morbidity, regardless of the availability of a number of treatment approaches, due to various challenges in drug treatment, which demands the development of new therapeutic approaches. The nanotechnological approach has shown great potential to overcome the major hurdles in stroke management and has provided a useful platform for the development of novel therapeutic methods for treatment ([@B180]).

Free radicals, which result in cellular and tissue damage, are considered as main contributing factors in the pathology of ischemic brain disease. The role of this contributing factor can be limited by the use of nano-therapeutic approach. Cerium oxide nanoparticles were demonstrated to possess antioxidant properties that supported cell survival and reduced the production of free radicals, as well as, were found to be non-toxic to neuronal (HT22) and macrophage (RAW164) cell lines ([@B182]). In another study, xenon gas, a small molecule that can readily cross the BBB and has favorable neuroprotective properties, was loaded into liposomes and administered for up to 5 h after stroke onset with an optimal dosage range of 7--14 mg/kg and found to diminish infarct size in a rat model ([@B157]). [Table 4](#T4){ref-type="table"} showing different types of nanocarriers used in acute ischemic stroke conditions.

###### 

Nanocarriers for neuroprotective therapy in acute ischemic stroke.

  Nanocarriers            Types of nanomaterials                  Drugs/Agents                                        Targeting ligands   Outcomes                                                           References
  ----------------------- --------------------------------------- --------------------------------------------------- ------------------- ------------------------------------------------------------------ ------------
  PNPs                    PLGA                                    Tissue factor specific siRNA                        EGFP-EGF1           Efficient RNA interference                                         [@B30]
                          Glutathione coated PLGA-b-PEG           Thyroid hormones                                    Glutathione         Protection against ischemic damage                                 [@B120]
                          PLGA                                    PEGylated epidermal growth factor, erythropoietin                       Attenuation of inflammatory response and improved neurogenesis     [@B214]
                          Chitosan                                bFGF                                                Transferrin         Reduced infarct volume                                             [@B229]
                          Gelatin                                 Osteopontin                                                             Reduced infarct volume and extended therapeutic volume             [@B75]
  Liposomes               Cholesterol, PEG2000-PE                 Minocycline                                                             Reduced TNF-α induced MMP-9 release                                [@B223]
                          DPPC, cholesterol, PEG2000-PE, Egg-PC   Xenon                                                                   Reduced infarct size                                               [@B157]
                          DSPC, DPPC, cholesterol                 Tacrolimus                                                              Reduced cerebral cell death, ameliorated motor function deficits   [@B50]
  Metal and metal oxide                                           Platinum                                                                ROS scavenging                                                     [@B198]
                                                                  Cerium oxide                                                            ROS scavenging                                                     [@B43]

DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; Egg-PC, egg phosphocholine; MMP-9, matrix metalloproteinase-9; PEG2000-PE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-\[methoxy (polyethyleneglycol)-2000\]; PLA, poly (lactic acid); PLGA, poly (D,L-lactide-co-glycolic acid); ROS, reactive oxygen species.

Nanotechnology Based Delivery of Neuroprotective Drugs {#S5}
======================================================

Free radicals, such as superoxide, hydroxyl, peroxynitrite, and peroxide, cause deleterious alterations in cells including DNA fragmentation, peroxidation of cell membrane lipids, mitochondrial energy disturbances and alteration in functionality of transporter proteins, they are considered as the main culprit having the key role in pathology of neurodegenerative, ischemic, and traumatic CNS disorders ([@B110]; [@B41]).

Neuroprotective compounds based on carbon-60 fullerene -- the molecules having a 3-D pattern of evenly spaced carbon atoms, have been fabricated by the application of nanotechnological approach ([@B41]). Fullerenols, hydroxyl functional group possessing fullerene derivatives, have been demonstrated to act as an antioxidant and free radical scavenger, due to which they are capable of reducing glutamate, N-methyl-d-aspartate (NMDA), Amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), and kainite induced excitotoxicity and apoptosis. The ability of these nano-structures to inhibit glutamate channels without affecting GABA (A) or taurine receptors as well as their capability to lower the glutamate-mediated intracellular calcium concentrations are the suggested mechanisms for fullerenol mediated neuroprotection ([@B73]; [@B41]).

Curcumin {#S5.SS1}
--------

Curcumin (diferuloylmethane), a biologically active and chief phenolic constituent of turmeric obtained from the rhizomes of *Curcuma longa Linn*, which in its crude form has been employed as a spice, dietary supplement, and as a component of various traditional medicines, has shown tremendous therapeutic efficacy in several disease ([@B28]). Being a natural antioxidant, curcumin has been found to possess many pharmacological activities including anti-inflammatory, antimicrobial, anticancer, the neuroprotective effect in neurodegenerative disorders ([Table 5](#T5){ref-type="table"}), in both preclinical and clinical studies. Furthermore, curcumin has demonstrated hepatoprotective, nephroprotective, cardioprotective, neuroprotective, hypoglycemic, antirheumatic behavior, among which its neuroprotective action against various neurodegenerative disorders has attracted the attention of researchers. Despite the wide medicinal applications of curcumin, its clinical implication is hindered due to low solubility, physico-chemical instability, poor bioavailability, rapid metabolism, and poor pharmacokinetic ([@B28]). However, these problems can be solved by developing efficient delivery system, and the nano-technological approach has provided a platform to handle all the hurdles for the efficient delivery and action of curcumin ([@B133]).

###### 

Evaluation of targeted curcumin nanoformulations for CNS therapeutics.

  Nanoformulations                                                                                                         Target disease         Outcomes                                                                                                                                                                                                                                                                                                               References
  ------------------------------------------------------------------------------------------------------------------------ ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Biodegradable PLGA-curcumin                                                                                              Alzheimer's Disease    Exhibit non-toxicity in human neuroblastoma SK-N-SH cells and protect from H~2~O~2~- induced rise in ROS. Able to prevent the induction of the redox-sensitive/transcription factor Nrf2 in the presence of H~2~O~2~, indicative approach to protect neurons against oxidative injury that is usually observed in AD   [@B40]
  PEG-liposomes with the anti-transferrin, lipid conjugate liposome, nanoliposomes, PEG--polylactic acid block copolymer   Alzheimer's Disease    Aggregation inhibition of Aβ                                                                                                                                                                                                                                                                                           [@B128]
  tApoE3-conjugated and Curcumin loaded PBCA polymer nanoparticles                                                         Alzheimer's disease    Treatment of Aβ-induced cytotoxicity in AD                                                                                                                                                                                                                                                                             [@B130]
  Curcumin-gold nanoparticles                                                                                              Alzheimer's disease    Interacted with amyloid protein/peptide and simultaneously diminish amyloid fibrillation and dissolve amyloid fibrils by acting as artificial molecular chaperones                                                                                                                                                     [@B146]
  Anti-amyloid antibody-Conjugated and curcumin/dexamethasone loaded gadolinium/magnetic nanoparticles                     Alzheimer's disease    Early diagnosis, effective targeting, and as a therapeutic agent(s) of cerebrovascular amyloid                                                                                                                                                                                                                         [@B71]
  PLGA-bPEG-triphenylphosphonium polymer (PLGA-b-PEG-TPP)-based curcumin nanoformulation                                   Huntington's disease   Confirmed significant cytosolic and mitochondrial fractions in cells, indicating mitochondria-targeting chemotherapeutics                                                                                                                                                                                              [@B115]
  Solid-lipid-based curcumin nanoformulation                                                                               Huntington's disease   Attenuated 3-nitropropionic-acid- induced Huntington's disease in rats by increasing complex II activity, restoring the glutathione and superoxide dismutase                                                                                                                                                           [@B178]
  Poly (N-isopropyl acrylamide)--curcumin nanoformulation                                                                  Ischemic stroke        Improved neurobehavioral activity and reduced cytokine levels (tumor necrosis factor alpha (TNF-α) and IL-1β) and reduces oxidative stress                                                                                                                                                                             [@B2]
  Solid lipid nanoparticles of curcumin                                                                                    Ischemic stroke        Alleviated behavioral, oxidative, and nitrosative stress; acetylcholinesterase; and mitochondrial enzyme complex, and physiological parameters in cerebral ischemic reperfusion injury in rats                                                                                                                         [@B79]

Different types of nano-carriers such as nanoparticles, micelles, nanocrystals, nano-emulsions, and nano-liposomes have fascinated the researchers in order to address problems related to poor bioavailability and pharmacokinetic of curcumin. In past few years, a lot of studies were carried out to find out the efficacy of various nanoformulations for better therapeutic activity. In a study, Joseph et al investigated the uptake and diffusion of curcumin loaded PLGA-PEG nanoparticles in neonatal rat brain. They observed neuroprotection against impaired blood--brain barrier in regions of injury. These nanoparticles diffuses effectively through the brain parenchyma ([@B77]). In another study, Zhang et al. formulated curcumin-loaded polysorbate 80 modified cerasome (CPC) nanoparticles and delivered them to the MPTP-induced PD mice by ultrasound-targeted microbubble destruction of BBB. They reported better stability, longer circulation time, and higher permeation of nanoformulation of curcumin as compared to bulk curcumin. Furthermore, they observed improved behavior disorder along with dopamine depletion after treatment with CPC NPs (15 mg curcumin/kg) ([@B134]). In *in-vitro* as well as *in-vivo* studies, PNPs encapsulated curcumin (NanoCurc^TM^) demonstrated better efficacy in protecting neurons from oxidative insults. NanoCurc^TM^ treatment protected human SK-N-SH cells from H~2~O~2~ mediated ROS insults. *In vivo*, intraperitoneal (IP) injection of NanoCurc^TM^ at a dose of 25 mg/kg twice daily in athymic mice demonstrated significant curcumin levels in the brain and resulted in decreased levels of H~2~O~2~, and caspases activities in brain along with increased glutathione concentrations ([@B167]). In a study, curcumin-encapsulated PLGA NPs (Cur-PLGA-NPs) demonstrated better effect on neural stem cell proliferation and neuronal differentiation *in vitro* as well as *in vivo*, as compared to bulk curcumin. Cur-PLGA-NPs significantly elevated expression of genes related to cell proliferation and neuronal differentiation in hippocampal region. They produced better effect on impaired learning and memory parameters in an Aβ induced rat model of AD. By *in silico* molecular docking studies it was found that these NPs induced neurogenesis through canonical Wnt/β-catenin pathway ([@B205]). Mathew et al synthesized a water soluble PLGA coated-curcumin NPs and coupled it with Tet-1 peptide, a peptide having high affinity to neurons. They found that curcumin encapsulated NPs successfully destroyed amyloid aggregates along with anti-oxidative property and non-cytotoxicity ([@B117]).

Growth Factors {#S5.SS2}
--------------

Various growth factors among which, Nerve growth factors (NGFs) are most essential, are needed for the development and phenotype maintenance of neurons in the peripheral nervous system and for the functional integrity of neurons in the CNS. NGFs have great therapeutic potential for various CNS disorders ([Table 6](#T6){ref-type="table"}). Vascular endothelial growth factor (VEGF) was considered as a potentially useful therapeutic agent to attenuate ischemic brain injury, as it has been shown to participate in the process of post-ischemic brain repair via promoting neurogenesis and cerebral angiogenesis. Thus, effective neuroprotection and promotion of vascular regeneration in the ischemic brain have been achieved by treatment with VEGF loaded transferrin-modified liposomes (Tf-LPs). [@B236] achieved enhanced delivery of VEGF to the ischemic brain by encapsulated VEGF-encoding plasmids in Tf-LPs. It was found that the rats treated with Tf-LPs exhibited increased levels of VEGF mRNA and protein in the ischemic brain, compared with the rats treated with unmodified liposomes or saline.

###### 

A brief summary of nanoformulations related to NGF.

  Activity                                  Type of nanoparticle   Functional coating                                    Outcomes                                                                                                                   References
  ----------------------------------------- ---------------------- ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------
  Differentiation and survival              Gold nanorods          Coated with poly (4-styrenesulfonic acid) or SiO~2~   Increase the differentiation of NG108-15 cells                                                                             [@B156]
                                            Iron oxide             Conjugated to NGF                                     Stabilize NGF and enhance neuronal differentiation                                                                         [@B113]
                                            Silver                                                                       Enhance the differentiation of SH-SY5Y cells                                                                               [@B6]
  Directing Neuronal migration and growth   Iron oxide                                                                   Apply magnetic tensile forces to cause SH-SY5Y and primary Schwann cell cultures to migrate toward predefined directions   [@B171]
                                            Iron oxide             Conjugated to NGF                                     Apply magnetic tensile forces to induce directed neurite sprout in PC12 cells                                              [@B170]

Edaravone {#S5.SS3}
---------

Edaravone (EDR), a well-known lipophilic drug, has shown great potential as a free radical scavenger for diseases including neurodegenerative disease, cardiovascular disease, and cancer. Recently, it has fascinated researchers as and has shown noteworthy pharmacological value against the incurable diseases like ALS and AD ([@B33]). No oral formulation of the EDR is currently available in the market and liquid formulation for the purpose of intravenous infusion is the only commercially available formulation. Though, oral bioavailability of EDR is very less, yet, it has shown great potential for AD, cerebral aneurysm via oral administration in preclinical studies ([@B68]). The EDR loaded lipid-based nanosystem (LNS) has been developed to facilitate its efficient oral delivery by augmenting the oral bioavailability. Solid-LNS showed elevated cellular uptake and better neuroprotective effect compared to EDR in SH-SY5Y695 cell line ([@B151]).

Obstacles to Clinical Translation {#S6}
=================================

The emerging role of nanotechnology in therapeutics is not untouched by the challenges and does not always demonstrate promising results but also has been associated with several risks ([Figure 6](#F6){ref-type="fig"}). Currently, nano-based approach is considered as a successful tool for delivery of drugs across BBB ([@B220]; [@B197]; [@B61]). Although, a number of nanomedicine are in its infancy in the preclinical and clinical studies, and still sufficient data required to prove them as a better approach over conventional neurotherapeutics ([@B39]). The composition of nanocarrier is the key determinant of its properties, and may be responsible for oxidative stress, amino acid disturbance and BBB disruption that cause neurotoxicity in the brain ([@B185]). Although, nanoparticles functionalized with specific ligands provide successful drug targeting, but their extremely small size and the large surface area may cause problems like particle aggregation, interparticular friction, limited drug loading and high clearance rate sufficient to preclude their use in diagnosis and drug delivery.

![Various challenges for the nanotechnology-based drug delivery.](fnins-14-00494-g006){#F6}

The increased surface area results in an augmented chemical reactivity of the nanoparticles which then increase the production of ROS and ultimately leads to toxicity, such as neuroinflammation, excitotoxicity, DNA damage and allergic responses. Toxicity pattern of the nanocarriers depends on its state of aggregation, mechanical properties, mode of drug administration ([@B210]). Therefore, biocompatibility and biodegradability of nano-drugs are also critical to be fully understood. As nanomedicines have to interact with neurons to show their response, multidimensional interaction at neuronal level and restricted anatomical access increase the challenges in nano-based drug delivery ([@B70]).

The ultimate goal of nano-mediated CNS drug-delivery systems is to engineer the nanocarriers to be safe and to enable their long term use without any adverse side effects which made them successful in clinical translation from bench to bedside.

Future Perspectives {#S7}
===================

Blood-brain barrier are the one of the pharmacologically active shield against CNS disorders. Brain-targeted drug delivery systems has been developed in last few recent years and gained large attention. The obstruction posed by BBB toward therapeutic drugs against diseased part of brain tissues, brain-targeted drug delivery systems seems to be the most promising strategy to address our natural defense system. A clear perceptive toward the functions of brain cells such as microglia, astrocytes, endothelial cells, and neural stem cells in neuro-disorders pathology is requisite in order to develop successful novel targeted-drug delivery systems. Even though, several nanoformulations have shown great efficacy in preclinical and clinical studies, their clinical translation from bench to bedside is not very successful due to inadequate information about their final fate in terms of toxicity, and other problems like aggregation and rapid clearance due to nano-size. In-depth and complete toxicological studies of brain targeting nanoformulations with their clear mechanism of action and pharmacokinetics with and without therapeutics should be essentially investigated. Besides this, more research has to be done in order to determine the fate of nanocarriers inside body, their systemic toxicity, biocompatibility, and RES elimination. The therapeutic potential of nanomedicine will rely on the rational approach and further designing of nanomaterials based on detailed and comprehensive knowledge of obtained from biological processes. Several basic concerns should be addressed in the future to achieve the successful clinical translation of nanoformulations:

1.  The nanomaterials should be biodegradable in nature and provide effective and safe brain-targeted drug delivery systems.

2.  An eco-friendly green approach should be developed for preparation of nanoformulations.

3.  The factors like shape, size, charge and moiety attached to nanomaterials should be well elucidated and evaluated, which is essential for crossing and developing brain-targeted drug delivery systems.

4.  A non- invasive alternative method for nanocarrier drug delivery should be developed in order to avoid complications such as poor patient compliance associated with i.v., and other invasive routes. Newer drug-administration routes for nanocarrier-mediated CNS drug-delivery systems such as oral, transbuccal, mucosal/sublingual, or nasal, need to be explored.

The main issue for bench to bedside translation of nanoformulations is toxicity which has to be dealt carefully. The fate and mechanism of nanocarriers with respect to their bulk counterparts should be studied in detail before it comes to market. Therefore, in near future, fundamental research has to be carried out to deal with these issues if the successful efficient application of nanoformulations has to be achieved.

Conclusion {#S8}
==========

Central nervous system diseases, such as AD, PD, stroke, brain tumors, and neuroinflammation have become distressful devastating to mankind due to the change in lifestyle and the rapid continued deterioration of the environment. BBB and BCSFB is the main physiological barrier which possess big bottleneck for the successful treatment of CNS disorders and brain tumors, complex anatomical structure, unique microenvironment, and their selectivity toward any foreign compound including drug is treated as a biggest challenge toward CNS drug delivery. High therapeutic drug concentration inside brain should be reached through effective and safe carrier, hence there is a need of developing good cargo, which carries drug to CNS in effective concentration without causing systemic side effects.

Nanomedicines have been implicated to address the problems related to treatment of neurological disorder and have a cutting edge over the conventional CNS therapy. Nanocarriers such as nanoparticles, liposomes, nanopharmaceuticals, nanotubes, nanoemulsions, nanosensors, dendrimers, and micelles, etc. are having high prospective in neuroprotection as theranostics. Engineered nanomaterials are designed by scientistist in order to increase its biocompatibility, blood circulation time and reduced their systemic toxicity, prevent the drug from degradation from physiological environment with sustained and controlled release along with the site-specific targeting. The current demand for the successful nano-based approaches focused on the regeneration and neuroprotection that will significantly benefit from continued nano based approach along with the advancement in neuronal cell biology their pathology and physiology. In models of AD, PD and stroke, different nanoscalic approaches have been identified to cure neurological disorders such as inhibition of Aβ oligomerization, reduce reactive oxygen species, and enhance functional neuronal networks. Nanocarriers have enabled targeted delivery of chemotherapeutics as well as antisense gene therapy, in malignant brain tumors, ensuing in remarkable inhibition of disease progression *in vitro* as well as *in vivo* study. Fortunately, a small number of these promising preclinical studies have been successfully translated to the clinic for effective patient care. Nanotechnology has been implicated in the development of nanoformulations of various neuroprotective drugs such as curcumin, nerve growth factors, and edaravone, etc. but still limited data are provided related to their adverse effects. Future perspective of use of nanotechnology in CNS drug delivery is very promising and it opens new avenues in the treatment of neurological disorders as it has the potential to fundamentally revolutionize the way we approach CNS-targeted therapeutics due to their ability to nanoengineered the drug/carriers to cross BBB, diffuse within the brain tissue, target specific cell, or signaling systems for delivering therapeutics.
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